ABEO
Abeona Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$271.55M
P/E Ratio
4.71
EPS
$1.01
Beta
1.21
52W High
$7.54
52W Low
$3.93
50-Day MA
$4.92
200-Day MA
$5.47
Dividend Yield
—
Profit Margin
1223.00%
Forward P/E
526.32
PEG Ratio
0.00
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $5.82M |
| Gross Profit (TTM) | $-24.42M |
| EBITDA | $-86.90M |
| Operating Margin | -422.70% |
| Return on Equity | 70.10% |
| Return on Assets | -34.00% |
| Revenue/Share (TTM) | $0.11 |
| Book Value | $2.89 |
| Price-to-Book | 1.73 |
| Price-to-Sales (TTM) | 46.66 |
| EV/Revenue | 18.65 |
| EV/EBITDA | 1.38 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $57.05M |
| Float | $45.46M |
| % Insiders | 15.68% |
| % Institutions | 69.48% |
Analyst Ratings
Consensus ($19.57 target)
6
BuyData last updated: 4/7/2026